Non-arteritic Anterior Ischemic Optic Neuropathy Sequela From Potential COVID-19-Associated Coagulopathy.

We report a case involving a post-menopausal female who experienced a sudden loss of peripheral vision in her right eye seven months after a confirmed COVID-19 infection. MRI scans of the brain and orbit excluded neuritis and multiple sclerosis, leading to the diagnosis of non-arteritic anterior ischemic optic neuropathy (NAION). It is known that the intense inflammatory condition resulting from acute respiratory distress syndrome triggered by SARS-CoV-2 infections can result in a heightened tendency for blood clot formation. Emerging research underscores the potential link between the likelihood of a thrombotic event in the eye as a consequence of COVID-19 infection and the development of NAION. The connection between NAION and COVID-19, whether it is correlative or coincidental, remains uncertain. However, this case report aims to present evidence for the plausibility of this link and offer insights into potential ophthalmologic complications caused by COVID-19.

Clobazam for the treatment of intractable epilepsy in children.

We describe our experience using clobazam, examining efficacy for individual seizure types and analyzing for factors contributing to initial and sustained response. We retrospectively reviewed medical charts of children treated with clobazam. We collected patient and treatment characteristics and compared response to therapy at 6, 12, and >12 months' duration. One hundred eight patients with a variety of seizure types and etiologies of epilepsy were treated. Response rates for >50% seizure reduction were 59%, 39%, and 30% of patients at 6, 12, and >12 months' therapy, respectively. No seizure type responded more favorably and there were no patient predictors of favorable response. Patients tended to respond early and at low dosing, and half the patients maintained this response for 15 months or more. Clobazam has efficacy against a wide spectrum of seizure types and epilepsy etiologies. An early, low-dose response is a favorable indicator for sustained response.

Amantadine for the treatment of refractory absence seizures in children.

Amantadine has demonstrated efficacy in small series for absence and myoclonic type seizures. We examined the efficacy of amantadine for treating refractory absence seizures in a cohort of pediatric patients. We retrospectively reviewed medical records for patients with absence seizures treated with amantadine at Cook Children's Medical Center after January 2007. Abstracted data included sex, age at initiation, concomitant antiepileptic drugs, amantadine dosing, and seizure frequency. Outcomes at 3, 6, and 12 months after initiation were categorized as >90%, ≥50%, or <50% reduction in seizure frequency. Of 13 patients included in the study, many were exposed to multiple antiepileptic drugs (median, 3; range, 1-6). Three were implanted with a vagus nerve stimulator. A response of at least 50% seizure reduction was reported in more than 50% of patients reviewed at 3, 6, and 12 months after initiating treatment. Among responders, a majority had >90% reduction in seizure frequency. Amantadine may constitute an efficacious alternative treatment for refractory absence seizures.

Uveal metastasis from nonsmall cell lung carcinoma with dramatic response to erlotinib.

PURPOSE: To report the case of a never-smoker patient whose initial presentation of metastatic nonsmall cell lung carcinoma was with uveal metastasis, which had a dramatic response to targeted biologic therapy with erlotinib (Tarceva) after failing conventional chemotherapy. METHODS: Case report. A 43-year-old man with uveal metastasis from nonsmall cell lung adenocarcinoma. RESULTS: After failing conventional chemotherapy with carboplatin and taxol, with continued documented rapid growth of the uveal metastasis, treatment was initiated with the targeted biologic agent, erlotinib, which is a protein tyrosine kinase inhibitor of the epidermal growth factor receptor(EGFR). Within 3 days of starting erlotinib, shrinkage of the choroidal lesion was noted, and over the course of the next 3 months, the tumor completely and durably disappeared, with vision improving from hand motion to 20/25. The patient is still alive and well after 3 years, on continued daily oral erlotinib treatment. CONCLUSION: Erlotinib is a well-tolerated newly available Food and Drug Administration-approved oral targeted biologic agent, which may be beneficial in some patients with uveal metastasis from nonsmall cell lung carcinoma, in which an underlying epidermal growth factor receptor mutation is suspected.